BMC Immunology

Table 3 Clinical response to Hu-rhEGF-rP64k vaccine

From: Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer

First evaluation [n (%)] Day 46
Response	Group A–0.6 mg	Group B- 1.2 mg	Group C-1.8 mg	Group D-2.4 mg	Total
Response	n = 3	n = 6	n = 5	n = 6	n = 20
CR	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
PR	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
SD	3(100%)	4(67%)	3(60%)	5(83%)	15(75%)
PD	0(0%)	2(33%)	2(40%)	1(17%)	5(25%)
Second evaluation [n (%)] Day 106
Response	Group A–0.6 mg	Group B- 1.2 mg	Group C-1.8 mg	Group D-2.4 mg	Total
Response	n = 3	n = 5	n = 3	n = 4	n = 15
CR	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
PR	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
SD	3(100%)	3(60%)	2(67%)	4(100%)	12(80%)
PD	0(0%)	2(40%)	1(33%)	0(0%)	3(20%)

Back to article page

ISSN: 1471-2172

Contact us

General enquiries: journalsubmissions@springernature.com